Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul 19:2010:2002.

End-stage renal disease

Maaz Ahmed Abbasi  1 , Glenn M Chertow, Yoshio N Hall
Affiliations

End-stage renal disease

Maaz Ahmed Abbasi et al. BMJ Clin Evid. .

Abstract

Introduction: End-stage renal disease (ESRD) affects more than 1500 people per million population in countries with a high prevalence, such as Japan, Taiwan, and the US. Approximately two-thirds of people with ESRD receive haemodialysis, one quarter have kidney transplants, and one tenth receive peritoneal dialysis.

Methods and outcomes: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of different doses for peritoneal dialysis? What are the effects of different doses and membrane fluxes for haemodialysis? What are the effects of interventions aimed at preventing secondary complications? We searched: Medline, Embase, The Cochrane Library, and other important databases up to October 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Results: We found 26 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.

Conclusions: In this systematic review we present information relating to the effectiveness and safety of the following interventions: cinacalcet, darbepoetin, erythropoietin, haemodialysis (standard-dose, increased-dose), high membrane-flux haemodialysis, increased-dose peritoneal dialysis, low membrane-flux haemodialysis, mupirocin, sevelamer, standard-dose dialysis, and statins.

PubMed Disclaimer

References

    1. National Kidney Foundation. Kidney Disease Quality Outcomes Initiative (K/DOQI). http://www.kidney.org/professionals/kdoqi/guidelines.cfm (last accessed 2 June 2010).
    1. Chertow GM. Slowing the progression of vascular calcification in hemodialysis. J Am Soc Nephrol 2003;14:S310–S314. - PubMed
    1. United States Renal Data System. 2009 Annual data report atlas of chronic kidney disease & end-stage renal disease in the United States. USRDS 2009.
    1. Stel VS, Kramer A, Zoccali C, et al. The 2007 ERA-EDTA registry annual report - a precis. NDT Plus 2009;2:514–521. - PMC - PubMed
    1. Australia and New Zealand Dialysis and Transplant Registry. 2008 Annual Report. ANZDATA 2008.

Publication types